CA2967897A1 - Methods for treating alzheimer's disease - Google Patents
Methods for treating alzheimer's disease Download PDFInfo
- Publication number
- CA2967897A1 CA2967897A1 CA2967897A CA2967897A CA2967897A1 CA 2967897 A1 CA2967897 A1 CA 2967897A1 CA 2967897 A CA2967897 A CA 2967897A CA 2967897 A CA2967897 A CA 2967897A CA 2967897 A1 CA2967897 A1 CA 2967897A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- body weight
- antibody
- dose
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 194
- 238000000034 method Methods 0.000 title claims abstract description 106
- 206010072599 Amyloid related imaging abnormalities Diseases 0.000 claims abstract description 102
- 238000011282 treatment Methods 0.000 claims abstract description 100
- 230000002829 reductive effect Effects 0.000 claims abstract description 45
- 230000037396 body weight Effects 0.000 claims description 205
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 52
- 208000024891 symptom Diseases 0.000 claims description 35
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims description 34
- 230000000737 periodic effect Effects 0.000 claims description 16
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 206010030113 Oedema Diseases 0.000 claims description 14
- 230000000982 vasogenic effect Effects 0.000 claims description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 9
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 206010067277 Cerebral microhaemorrhage Diseases 0.000 claims description 4
- 239000000902 placebo Substances 0.000 description 34
- 229940068196 placebo Drugs 0.000 description 34
- 230000009467 reduction Effects 0.000 description 33
- 108010025628 Apolipoproteins E Proteins 0.000 description 30
- 102000013918 Apolipoproteins E Human genes 0.000 description 30
- 239000000969 carrier Substances 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 206010012289 Dementia Diseases 0.000 description 27
- 210000004556 brain Anatomy 0.000 description 26
- 229950008995 aducanumab Drugs 0.000 description 22
- 238000002600 positron emission tomography Methods 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 208000032843 Hemorrhage Diseases 0.000 description 20
- 230000008859 change Effects 0.000 description 18
- 231100000673 dose–response relationship Toxicity 0.000 description 17
- 238000004448 titration Methods 0.000 description 15
- YNDIAUKFXKEXSV-CRYLGTRXSA-N florbetapir F-18 Chemical compound C1=CC(NC)=CC=C1\C=C\C1=CC=C(OCCOCCOCC[18F])N=C1 YNDIAUKFXKEXSV-CRYLGTRXSA-N 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 208000037259 Amyloid Plaque Diseases 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 9
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 9
- 239000000090 biomarker Substances 0.000 description 9
- 230000002490 cerebral effect Effects 0.000 description 9
- 230000001149 cognitive effect Effects 0.000 description 9
- 239000002131 composite material Substances 0.000 description 9
- 238000002595 magnetic resonance imaging Methods 0.000 description 9
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 208000031856 Haemosiderosis Diseases 0.000 description 8
- 208000035868 Vascular inflammations Diseases 0.000 description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 230000007170 pathology Effects 0.000 description 8
- 238000012879 PET imaging Methods 0.000 description 7
- 230000001174 ascending effect Effects 0.000 description 7
- 208000010877 cognitive disease Diseases 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 6
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 6
- 230000019771 cognition Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000015654 memory Effects 0.000 description 6
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 6
- 102000013498 tau Proteins Human genes 0.000 description 6
- 108010026424 tau Proteins Proteins 0.000 description 6
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229950001863 bapineuzumab Drugs 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000011830 transgenic mouse model Methods 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 208000027061 mild cognitive impairment Diseases 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000008719 thickening Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 230000009760 functional impairment Effects 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000006996 mental state Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000001936 parietal effect Effects 0.000 description 3
- 230000008289 pathophysiological mechanism Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 208000023366 superficial siderosis Diseases 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 238000010176 18-FDG-positron emission tomography Methods 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000007792 alzheimer disease pathology Effects 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000006736 behavioral deficit Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000004980 dosimetry Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000051 modifying effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000001423 neocortical effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000003557 neuropsychological effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 101150047829 plin-1 gene Proteins 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- YNDIAUKFXKEXSV-NSCUHMNNSA-N 4-[(e)-2-[6-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]-n-methylaniline Chemical compound C1=CC(NC)=CC=C1\C=C\C1=CC=C(OCCOCCOCCF)N=C1 YNDIAUKFXKEXSV-NSCUHMNNSA-N 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 229940124717 Alzheimer's therapeutics Drugs 0.000 description 1
- 241000270491 Ameiva Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- BPNZYADGDZPRTK-UDUYQYQQSA-N Exametazime Chemical compound O/N=C(\C)[C@@H](C)NCC(C)(C)CN[C@H](C)C(\C)=N\O BPNZYADGDZPRTK-UDUYQYQQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 108010017480 Hemosiderin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010071176 Impaired reasoning Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000276398 Opsanus tau Species 0.000 description 1
- 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
- 101710133394 POU domain, class 3, transcription factor 2 Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000020466 alteration of consciousness Diseases 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000011952 auditory verbal learning test Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000006741 behavioral dysfunction Effects 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000001073 episodic memory Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000035557 fibrillogenesis Effects 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000004124 hock Anatomy 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002075 inversion recovery Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000003976 synaptic dysfunction Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086674P | 2014-12-02 | 2014-12-02 | |
| US62/086,674 | 2014-12-02 | ||
| US201562111874P | 2015-02-04 | 2015-02-04 | |
| US62/111,874 | 2015-02-04 | ||
| US201562149133P | 2015-04-17 | 2015-04-17 | |
| US62/149,133 | 2015-04-17 | ||
| US201562195119P | 2015-07-21 | 2015-07-21 | |
| US62/195,119 | 2015-07-21 | ||
| PCT/IB2015/002465 WO2016087944A2 (en) | 2014-12-02 | 2015-12-02 | Method for treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2967897A1 true CA2967897A1 (en) | 2016-06-09 |
Family
ID=55358010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2967897A Pending CA2967897A1 (en) | 2014-12-02 | 2015-12-02 | Methods for treating alzheimer's disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10842871B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3227329A2 (cg-RX-API-DMAC7.html) |
| JP (5) | JP2017537905A (cg-RX-API-DMAC7.html) |
| KR (3) | KR20240152957A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2015356773B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2967897A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201791199A1 (cg-RX-API-DMAC7.html) |
| IL (3) | IL311405A (cg-RX-API-DMAC7.html) |
| MA (1) | MA41115A (cg-RX-API-DMAC7.html) |
| MX (2) | MX385045B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016087944A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202107358B (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| KR20190021311A (ko) * | 2016-06-07 | 2019-03-05 | 바이오겐 인터내셔널 뉴로사이언스 게엠베하 | 알츠하이머병의 치료 방법 |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| CA3032289A1 (en) * | 2016-07-29 | 2018-02-01 | Biogen Chesapeake Llc | Methods of treating or preventing amyloid related imaging abnormalities associated with alzheimer's disease treatment |
| CA3042020A1 (en) * | 2016-10-27 | 2018-05-03 | Eisai R&D Management Co., Ltd. | Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease |
| US10662226B2 (en) | 2016-10-28 | 2020-05-26 | The Regents of the University of Caiifomia | Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| MA49947B1 (fr) | 2017-08-22 | 2023-03-31 | Biogen Ma Inc | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes |
| AU2019309938A1 (en) * | 2018-07-24 | 2021-03-11 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| CA3127113A1 (en) | 2019-01-30 | 2020-08-06 | Dongxu Sun | Anti-gal3 antibodies and uses thereof |
| BR112022007595A2 (pt) * | 2019-10-22 | 2022-08-23 | Biogen Ma Inc | Métodos para tratar doença de alzheimer |
| AU2021278935A1 (en) | 2020-05-26 | 2022-12-08 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| UY39337A (es) | 2020-07-23 | 2022-02-25 | Othair Prothena Ltd | Anticuerpos anti-abeta |
| US20240270830A1 (en) * | 2021-06-07 | 2024-08-15 | Biogen Ma Inc. | Methods for treating alzheimer's disease |
| MX2023014719A (es) | 2021-06-11 | 2024-02-15 | Sage Therapeutics Inc | Esteroide neuroactivo para el tratamiento de la enfermedad de alzheimer. |
| KR102753583B1 (ko) | 2021-11-11 | 2025-01-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물 |
| EP4499154A1 (en) | 2022-03-25 | 2025-02-05 | REGENXBIO Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
| US20250296968A1 (en) | 2022-04-25 | 2025-09-25 | Tokyo Metropolitan Institute Of Medical Science | Variant neurodegenerative disease-associated protein |
| US20230360721A1 (en) * | 2022-05-03 | 2023-11-09 | Hoffmann-La Roche Inc. | In silico predictions of amyloid-related imaging abnormalities |
| TW202508603A (zh) | 2023-05-02 | 2025-03-01 | 美商賽吉醫療公司 | 神經活性類固醇調配物及其使用方法 |
Family Cites Families (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| AU702293B2 (en) | 1993-10-27 | 1999-02-18 | Athena Neurosciences, Inc. | Transgenic animals harboring APP allele having Swedish mutation |
| US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| JP3816111B2 (ja) | 1997-04-09 | 2006-08-30 | インテレクト・ニューロサイエンシズ・インコーポレーテッド | β−アミロイド末端に特異的な組換え抗体、それをコードするＤＮＡ及びその使用法 |
| US20020086847A1 (en) | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
| US6703015B1 (en) | 1999-09-03 | 2004-03-09 | Ramot At Tel-Aviv University Ltd. | Filamentous bacteriophage displaying an β-amyloid epitope |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
| US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
| AU3117799A (en) | 1998-03-30 | 1999-10-18 | Trustees Of The University Of Pennsylvania, The | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| CA2349434A1 (en) | 1999-09-03 | 2001-03-15 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| US6713058B2 (en) | 1999-09-14 | 2004-03-30 | Milkhaus Laboratory, Inc. | Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies |
| US6436401B1 (en) | 1999-09-14 | 2002-08-20 | Milkhaus Laboratory, Inc. | Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies |
| US6294171B2 (en) | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
| US6187309B1 (en) | 1999-09-14 | 2001-02-13 | Milkaus Laboratory, Inc. | Method for treatment of symptoms of central nervous system disorders |
| WO2001031056A2 (fr) | 1999-10-27 | 2001-05-03 | Universite De Liege | Methode de detection par pcr |
| CA2412494C (en) | 2000-06-22 | 2012-10-23 | Genentech, Inc. | Agonist anti-trk-c monoclonal antibodies |
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| EP1172378A1 (en) | 2000-07-12 | 2002-01-16 | Richard Dr. Dodel | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
| US20030028904A1 (en) | 2001-04-19 | 2003-02-06 | Gumienny Tina L. | Genes involved in engulfment of dying cells and cell migration |
| DK1944040T3 (da) | 2001-08-17 | 2012-10-29 | Univ Washington | Analysefremgangsmåde for Alzheimers sygdom |
| US7414111B2 (en) | 2001-09-19 | 2008-08-19 | Alexion Pharmaceuticals, Inc. | Engineered templates and their use in single primer amplification |
| GB0203446D0 (en) | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| AU2003218560B2 (en) | 2002-04-19 | 2009-09-03 | The Governing Council Of The University Of Toronto | Immunological methods and compositions for the treatment of alzheimer's disease |
| US20110200609A1 (en) | 2002-09-12 | 2011-08-18 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence |
| CA2501945A1 (en) | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| DE60331101D1 (de) | 2002-11-22 | 2010-03-11 | Chugai Pharmaceutical Co Ltd | Antikörper gegen geschädigtes gewebe |
| BRPI0403964B8 (pt) | 2003-04-04 | 2021-05-25 | Genentech Inc | formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige |
| WO2004095031A1 (en) | 2003-04-24 | 2004-11-04 | Universität Zürich | Method of monitoring immunotherapy |
| TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
| WO2005018424A2 (en) | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| US20060094064A1 (en) | 2003-11-19 | 2006-05-04 | Sandip Ray | Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids |
| AU2005217596B2 (en) | 2004-02-23 | 2012-01-19 | Eli Lilly And Company | Anti-ABeta antibody |
| US7456027B2 (en) | 2004-04-15 | 2008-11-25 | University Of Florida Research Foundation, Inc. | Proteolytic biomarkers for traumatic injury to the nervous system |
| US7763249B2 (en) | 2004-04-27 | 2010-07-27 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human anti-amyloid β peptide antibody and fragment of said antibody |
| ATE476993T1 (de) | 2004-06-07 | 2010-08-15 | Univ Ramot | Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| US20060062859A1 (en) | 2004-08-05 | 2006-03-23 | Kenneth Blum | Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes |
| EA013752B1 (ru) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний |
| WO2006050041A2 (en) | 2004-10-28 | 2006-05-11 | Ramot At Tel Aviv University Ltd. | Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis |
| ES2396555T3 (es) | 2004-12-15 | 2013-02-22 | Janssen Alzheimer Immunotherapy | Anticuerpos que reconocen péptido beta amiloide |
| PE20061401A1 (es) | 2004-12-15 | 2006-12-23 | Neuralab Ltd | ANTICUERPOS Aß PARA MEJORAR LA COGNICION |
| KR20080021585A (ko) | 2005-03-05 | 2008-03-07 | 애보트 게엠베하 운트 콤파니 카게 | 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법 |
| JP2006265189A (ja) | 2005-03-24 | 2006-10-05 | Kyoto Univ | βアミロイドペプチド、及びそれを用いたアルツハイマー病治療薬又は予防薬のスクリーニング方法 |
| ES2318918B1 (es) | 2005-04-01 | 2010-02-16 | Biotherapix Molecular Medicines, S.L.U. | Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones. |
| WO2006116192A2 (en) | 2005-04-21 | 2006-11-02 | Medarex, Inc. | Irta-1 antibodies and their uses |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| WO2007011907A2 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| WO2007021255A1 (en) | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| EP1951237A2 (en) | 2005-11-14 | 2008-08-06 | The Trustees of Columbia University in The City of New York | Imaging correlates of neurogenesis with mri |
| EP1951892A4 (en) | 2005-11-22 | 2009-01-14 | Univ Pennsylvania | ANTIBODY TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISEASES |
| JP2009518010A (ja) | 2005-11-30 | 2009-05-07 | アボット・ラボラトリーズ | ヒトβアミロイドタンパク質の組み換え形態の調製方法及びこれらのタンパク質の使用 |
| EP1954718B1 (en) | 2005-11-30 | 2014-09-03 | AbbVie Inc. | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
| EP1954311A4 (en) * | 2005-12-07 | 2009-12-23 | Medarex Inc | CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY |
| KR101591223B1 (ko) | 2005-12-12 | 2016-02-04 | 에이씨 이뮨 에스.에이. | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| SI2436696T1 (sl) | 2007-01-05 | 2017-10-30 | University Of Zurich | Anti-beta-amiloidno protitelo in načini njegove uporabe |
| AU2008204901A1 (en) | 2007-01-09 | 2008-07-17 | Wyeth | Anti-IL-13 antibody formulations and uses thereof |
| PL2583978T3 (pl) | 2007-02-23 | 2016-07-29 | Prothena Biosciences Ltd Co | Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych |
| MX2009009926A (es) | 2007-03-13 | 2010-03-15 | Univ Zuerich | Anticuerpo tumor-especifico humano monoclonal. |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| JP2011526240A (ja) | 2007-04-18 | 2011-10-06 | ヤンセン アルツハイマー イミュノセラピー | 脳アミロイド血管症の予防および治療 |
| JP2008309778A (ja) | 2007-05-11 | 2008-12-25 | Daiichi Sankyo Co Ltd | ポリペプチドの検出又は定量方法、及び装置 |
| CN101778867A (zh) | 2007-06-08 | 2010-07-14 | 地中海大学 | 用于治疗胰腺肿瘤的组合物和方法 |
| US8022268B2 (en) | 2007-06-11 | 2011-09-20 | The University Of Zurich | Transgenic animal model for alzheimer's disease |
| DK2182983T3 (da) | 2007-07-27 | 2014-07-14 | Janssen Alzheimer Immunotherap | Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer |
| US9370531B2 (en) | 2007-08-31 | 2016-06-21 | New York University | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
| EP2185592B1 (en) | 2007-09-13 | 2013-01-23 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| RU2504551C2 (ru) | 2007-09-26 | 2014-01-20 | УЗ ФАРМА ГмбХ | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста |
| CA2696417A1 (en) | 2007-10-02 | 2009-04-09 | Csl Limited | Therapeutic antibody purification method and method of use |
| US7771957B2 (en) | 2007-10-19 | 2010-08-10 | The Regents Of The University Of California | Method for diagnosing alzheimer's disease |
| JPWO2009051220A1 (ja) | 2007-10-19 | 2011-03-03 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| GB0720912D0 (en) | 2007-10-25 | 2007-12-05 | Univ Cardiff | Monoclonal Anitbody for APP |
| KR20100097651A (ko) | 2007-10-29 | 2010-09-03 | 인썸 | 베타-아밀로이드 펩티드에 특이적인 신규 항체 및 진단제 또는 진단약으로서의 그 용도 |
| PT2207568T (pt) | 2007-11-16 | 2017-09-01 | Univ Rockefeller | Anticorpos específicos para a forma de protofibrilha da proteína beta-amilóide |
| EP2261254A3 (en) | 2007-12-21 | 2011-04-13 | Amgen, Inc | Anti-amyloid antibodies and uses thereof |
| WO2009094592A2 (en) | 2008-01-23 | 2009-07-30 | Perlegen Sciences, Inc. | Genetic basis of alzheimer's disease and diagnosis and treatment thereof |
| CA2714413C (en) | 2008-02-08 | 2017-01-24 | Immunas Pharma, Inc. | Antibody capable of binding specifically to ab-oligomer, and use thereof |
| EP3470079A1 (en) | 2008-04-29 | 2019-04-17 | BioArctic AB | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
| CA2730073A1 (en) | 2008-07-09 | 2010-01-14 | University Of Zurich | Method of promoting neurogenesis |
| WO2010032059A2 (en) | 2008-09-19 | 2010-03-25 | Medimmune Llc | Targeted binding agents directed to cd105 and uses thereof |
| PT2365804E (pt) | 2008-11-13 | 2015-09-16 | Modgene Llc | Redução da carga da beta-amiloide em tecido não cerebral |
| EA030826B1 (ru) | 2008-12-19 | 2018-10-31 | Панима Фармасьютикалз Аг | ЧЕЛОВЕЧЕСКИЕ АУТОАНТИТЕЛА ПРОТИВ α-СИНУКЛЕИНА |
| JP5812418B2 (ja) | 2009-04-17 | 2015-11-11 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| US20110237537A1 (en) | 2009-05-29 | 2011-09-29 | Lombard Jay L | Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis |
| JP5599454B2 (ja) | 2009-08-06 | 2014-10-01 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| CN102574915B (zh) | 2009-08-06 | 2014-10-22 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
| WO2011064225A1 (en) | 2009-11-24 | 2011-06-03 | Probiodrug Ag | Novel diagnostic method for the diagnosis of alzheimer's disease or mild cgnitive impairment |
| EP2510098B1 (en) | 2009-12-09 | 2015-02-11 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
| US20110152341A1 (en) | 2009-12-22 | 2011-06-23 | Probiodrug Ag | Cleavage of b-amyloid precursor protein |
| US9297808B2 (en) | 2010-07-07 | 2016-03-29 | Thermo Fisher Scientific Gmbh | Analyte mass spectrometry quantitation using a universal reporter |
| SI3042917T1 (en) | 2010-08-12 | 2018-04-30 | Eli Lilly And Company | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
| PT2627672T (pt) | 2010-10-11 | 2018-11-16 | Univ Zuerich | Anticorpos anti-tau humanos |
| JP6067575B2 (ja) | 2010-12-17 | 2017-01-25 | ニューリミューン ホールディング エイジー | ヒト抗ｓｏｄ１抗体 |
| WO2012174262A2 (en) | 2011-06-14 | 2012-12-20 | Cenestra Llc | Formulations and methods of treating subjects having central nervous system, endocrine, inflammatory or cardiovascular disorders or at-risk thereof with highly purified omega-3 fatty acid formulations |
| GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2013061163A2 (en) | 2011-10-28 | 2013-05-02 | Biogen Idec International Neuroscience Gmbh | Tdp-43 specific binding molecules |
| US20130164367A1 (en) | 2011-12-08 | 2013-06-27 | The Board Of Regents Of The University Of Texas System | Treatment of neurodegenerative disease with creb-binding protein |
| ITRM20120383A1 (it) | 2012-03-20 | 2013-09-21 | Uni Degli Studi Di Milano B Icocca | Metodo e kit per la rivelazione di anticorpi. |
| CN112225808A (zh) | 2012-09-12 | 2021-01-15 | 生物控股有限公司 | 人胰岛淀粉样多肽（hiapp）特异性抗体及其用途 |
| WO2014089500A1 (en) | 2012-12-07 | 2014-06-12 | Biogen Idec International Neuroscience Gmbh | A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES |
| US20140274764A1 (en) | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict response to treatments for mental disorders |
| US20140272950A1 (en) | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict ssri response |
| ES2740127T3 (es) * | 2013-05-06 | 2020-02-05 | Baxalta Inc | Tratamiento de subpoblaciones con enfermedad de Alzheimer con inmunoglobulina G combinada |
| EP3019629A4 (en) | 2013-07-12 | 2017-01-18 | Biogen International Neuroscience GmbH | Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease |
| SI3083681T1 (sl) | 2013-12-20 | 2020-10-30 | Neurimmune Holding Ag | Terapija transtiretin (TTR) amiloidoze in iz človeka izvirajoča protitelesa |
| NZ723884A (en) | 2014-02-08 | 2023-02-24 | Genentech Inc | Methods of treating alzheimer’s disease |
| WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| WO2015191825A1 (en) | 2014-06-13 | 2015-12-17 | Biogen Ma Inc. | Methods for the detection and measurement of amyloid beta in biological samples |
| CN107074937B (zh) | 2014-07-29 | 2021-07-27 | 神经免疫控股公司 | 人源抗亨廷顿蛋白(htt)抗体及其用途 |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| WO2017157961A1 (en) | 2016-03-14 | 2017-09-21 | Biogen International Neuroscience Gmbh | Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins |
-
2015
- 2015-12-01 MA MA041115A patent/MA41115A/fr unknown
- 2015-12-02 EP EP15834670.0A patent/EP3227329A2/en active Pending
- 2015-12-02 WO PCT/IB2015/002465 patent/WO2016087944A2/en not_active Ceased
- 2015-12-02 EA EA201791199A patent/EA201791199A1/ru unknown
- 2015-12-02 KR KR1020247033653A patent/KR20240152957A/ko active Pending
- 2015-12-02 IL IL311405A patent/IL311405A/en unknown
- 2015-12-02 US US15/531,960 patent/US10842871B2/en active Active
- 2015-12-02 KR KR1020177015204A patent/KR20170088360A/ko not_active Ceased
- 2015-12-02 MX MX2017006789A patent/MX385045B/es unknown
- 2015-12-02 CA CA2967897A patent/CA2967897A1/en active Pending
- 2015-12-02 KR KR1020227010447A patent/KR20220044874A/ko not_active Ceased
- 2015-12-02 AU AU2015356773A patent/AU2015356773B2/en active Active
- 2015-12-02 IL IL285722A patent/IL285722B2/en unknown
- 2015-12-02 JP JP2017527872A patent/JP2017537905A/ja not_active Withdrawn
-
2017
- 2017-05-22 IL IL252433A patent/IL252433B/en unknown
- 2017-05-24 MX MX2021009053A patent/MX2021009053A/es unknown
-
2020
- 2020-01-15 JP JP2020004429A patent/JP2020055880A/ja not_active Withdrawn
-
2021
- 2021-08-04 JP JP2021127999A patent/JP2021169536A/ja not_active Withdrawn
- 2021-09-30 ZA ZA2021/07358A patent/ZA202107358B/en unknown
- 2021-12-08 AU AU2021282448A patent/AU2021282448A1/en not_active Abandoned
-
2022
- 2022-11-25 JP JP2022188107A patent/JP2023011002A/ja not_active Withdrawn
-
2025
- 2025-02-21 AU AU2025201237A patent/AU2025201237A1/en active Pending
- 2025-10-03 JP JP2025167679A patent/JP2025182058A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202107358B (en) | 2025-01-29 |
| EP3227329A2 (en) | 2017-10-11 |
| MX2021009053A (es) | 2021-09-21 |
| JP2020055880A (ja) | 2020-04-09 |
| IL252433B (en) | 2021-09-30 |
| KR20220044874A (ko) | 2022-04-11 |
| JP2021169536A (ja) | 2021-10-28 |
| KR20170088360A (ko) | 2017-08-01 |
| AU2025201237A1 (en) | 2025-03-20 |
| IL311405A (en) | 2024-05-01 |
| IL285722B2 (en) | 2024-08-01 |
| IL285722B1 (en) | 2024-04-01 |
| NZ731520A (en) | 2021-08-27 |
| JP2025182058A (ja) | 2025-12-11 |
| EA201791199A1 (ru) | 2017-09-29 |
| WO2016087944A3 (en) | 2016-08-04 |
| JP2017537905A (ja) | 2017-12-21 |
| US10842871B2 (en) | 2020-11-24 |
| IL285722A (en) | 2021-09-30 |
| MA41115A (fr) | 2017-10-10 |
| AU2015356773A1 (en) | 2017-05-25 |
| WO2016087944A2 (en) | 2016-06-09 |
| JP2023011002A (ja) | 2023-01-20 |
| IL252433A0 (en) | 2017-07-31 |
| MX2017006789A (es) | 2018-01-11 |
| KR20240152957A (ko) | 2024-10-22 |
| US20180333487A1 (en) | 2018-11-22 |
| AU2015356773B2 (en) | 2021-09-09 |
| NZ770434A (en) | 2024-10-25 |
| MX385045B (es) | 2025-03-14 |
| AU2021282448A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10842871B2 (en) | Methods for treating Alzheimer's disease | |
| US20220281963A1 (en) | Methods for treating alzheimer's disease | |
| US20220372123A1 (en) | Anti-beta-amyloid antibody for treating alzheimer's disease | |
| JP2024540294A (ja) | アルツハイマー病を治療するための方法 | |
| NZ788486A (en) | Methods for treating Alzheimer's disease | |
| US20240270830A1 (en) | Methods for treating alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201201 |
|
| EEER | Examination request |
Effective date: 20201201 |
|
| EEER | Examination request |
Effective date: 20201201 |
|
| EEER | Examination request |
Effective date: 20201201 |
|
| EEER | Examination request |
Effective date: 20201201 |
|
| EEER | Examination request |
Effective date: 20201201 |
|
| EEER | Examination request |
Effective date: 20201201 |